Reesha Bodiwala

Reesha Bodiwala

Auto-generated profile, based on publicly available information

Reesha Bodiwala

Marshall University Joan C Edwards School of Medicine Department of Internal Medicine, Huntington, WV, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
JAJowan Al-Nusair
Jowan Al-Nusair
RBReesha Bodiwala
Reesha Bodiwala
KNKemnasom Nwanwene
Kemnasom Nwanwene
MAMahmoud Abdallah
Mahmoud Abdallah
MAMohamed Alshal
Mohamed Alshal
TPToni Pacioles
Toni Pacioles
Lung cancer, a leading cause of cancer mortality, often involves epidermal growth factor receptor (EGFR) mutations, common in 17% of Caucasian and 40% of Asian non-small-cell lung cancer (NSCLC) patients. While the exon 19 deletion and L858R mutation are prevalent, rare variants like L833V/H835L are less understood. This case reports a 75-year-old female with NSCLC harboring L833V/H835L mutations. Initial imaging showed a right upper lobe mass and nodularity in the left upper lobe. Biopsy confirmed adenocarcinoma, and genomic analysis identified EGFR L833V/H835L mutations. Based on these findings, the patient was treated with osimertinib 160 mg daily, reduced to 80 mg due to side effects. After 3 months, positron emission tomography (PET) scans revealed significant tumor reduction, and brain metastasis remained stable. This case demonstrates the efficacy of osimertinib for rare EGFR mutations, aligning with literature suggesting its potential for managing such variants. Although large-scale trials are impractical due to the rarity of these mutations, this report adds valuable evidence supporting osimertinib’s use, highlighting the need for comprehensive genomic profiling in NSCLC.

1 May 2025 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
TWThomas D Wright
Thomas D Wright
JAJowan Al-Nusair
Jowan Al-Nusair
RBReesha Bodiwala
Reesha Bodiwala
SGSamhitha Gundakaram
Samhitha Gundakaram
SSSwapna Sirigireddy
Swapna Sirigireddy
MJMuhammad Omer Jamil
Muhammad Omer Jamil
Primary breast lymphoma (PBL) is a rare type of non-Hodgkin’s lymphoma, comprising less than 1% of all lymphomas and 0.5% of breast malignancies. The majority of PBL cases are of B-cell origin, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype, though follicular lymphoma (FL) also occurs. We present a case of a 74-year-old woman whose routine mammogram revealed a 1.5 cm mass in the right breast. Ultrasound and biopsy confirmed the presence of classic follicular lymphoma, with B-cell markers CD20, CD10, Bcl-6, and Bcl-2. A PET scan and biopsy of the left periaortic lymph node identified additional disease, confirming stage III FL. The patient was asymptomatic and exhibited favorable prognostic factors, including normal beta-2 microglobulin and LDH levels. Due to the indolent nature of her disease and low tumor burden, the decision was made to pursue active surveillance rather than immediate treatment. This case highlights the diagnostic challenges of PBL and the importance of personalized management, particularly in asymptomatic patients with low disease burden.